Clinic Marketing in Korea: Eight Medical-Advertising Risks to Check

In a targeted review of online medical advertisements, Korea's Ministry of Health and Welfare and medical-advertising review bodies referred 366 of 409 items to local authorities because of clear or substantial indications of illegality. Monitoring ran from December 11, 2023 to February 10, 2024; the results were announced on March 11, 2024.

That is approximately 89.5% of the items examined. It describes a selected monitoring sample, not the percentage of all clinics breaking the law. Being referred for action is different from being convicted.

The announcement summarized potential criminal and administrative consequences: up to three years' imprisonment or KRW 30 million for unlawful patient inducement or brokerage, and up to one year or KRW 10 million for false or exaggerated medical advertising. It also cited administrative suspension standards. The applicable sanction depends on the conduct, provision and case; a maximum is not an automatic sentence.

A clinic remains responsible for checking the advertising it publishes, including material prepared by an agency. This guide explains two important starting provisions, eight recurring risks, a wording review table and the application process. The Korean original was published April 26, 2026; this English edition checks legal sources as of October 31, 2026 and provides general marketing guidance, not a legal clearance of a particular advertisement.

1. Articles 56 and 57: two starting points for a medical-advertising review

Article 56: prohibited advertisers, content and methods

The Medical Service Act defines medical advertising and restricts who may undertake it. It also prohibits specified content and methods.

1. Who advertises: the provision restricts medical advertising to the specified medical-institution founders, heads and medical professionals. An agency relationship does not remove the need to establish the lawful advertising party.

2. Fifteen listed categories: these include unevaluated new medical technology, misleading treatment experiences, falsehoods, prohibited comparisons or disparagement, exposed surgical scenes, omitted material risk information, exaggeration, unsupported qualifications, certain news-like or expert-opinion advertisements, unreviewed or altered advertisements, prohibited domestic foreign-patient recruitment advertising, misleading non-covered fee discounts, restricted awards or endorsements, and other prescribed harmful content. Statutory qualifications and exceptions matter.

3. Review where required: Article 57 identifies the media and circumstances in which advance review is necessary. An advertisement outside that review requirement still has to comply with the content rules.

Article 57: review requirements, exceptions and validity

Eligible professional associations and qualifying registered consumer organizations can perform review after meeting the statutory requirements and notifying the ministry.
Approval is valid for three years from approval of the application. Article 57(9) requires an application six months before expiry to continue afterward; paragraph 8 establishes the three-year validity.
The relevant review route depends on the profession and institution: medical, dental or Korean medicine. Confirm the competent body and current instructions before applying.

These provisions are useful starting points. There is no evidence that knowing two articles alone resolves 90% of legal risk; patient inducement, privacy, qualifications and other applicable rules need attention too.

2. Eight recurring medical-advertising risks

The 2024 announcement counted 366 advertisements containing 506 potentially unlawful content items, because one advertisement could raise several issues. The following eight categories are a practical checklist, not a statistical ranking of all eight types.

1. Sponsored treatment experiences presented as independent reviews

The announcement reported 183 testimonial-related items. Its printed figure of 31.7% does not reconcile with the stated total of 506 content items: 183 divided by 506 is approximately 36.2%. We retain the reported count and flag the inconsistency rather than treating the printed percentage as a verified share.

Provision: Article 56(2)(2), concerning treatment experiences and other content that may mislead consumers about effects.
Risk example: a paid or sponsored treatment story presented as an independent patient recommendation. Disclosing payment does not automatically make the underlying medical advertisement permissible.
Review direction: assess the actual content, advertiser, medium and privacy arrangements. Consent, anonymity and describing a “patient case” do not create a general exemption.

2. Misleading discounts or waivers of non-covered treatment fees

The announcement reported 135 content items, or 26.7% of the 506-item total.

Provision: Article 56(2)(13), addressing discounts or waivers presented in a way that deceives or misleads consumers.
Risk example: an unexplained “50% off” comparison, waived patient copayments for referrals, or treatment refunds tied to reviews. The exact facts can also raise patient-inducement issues.
Review direction: disclose accurate fees, included and additional items, eligibility and dates where applicable. A genuine non-covered fee discount is not automatically prohibited simply because it is a discount; assess its presentation and the relevant rules.

3. False or exaggerated claims

The announcement reported 126 content items, or 24.9%.

Provisions: Article 56(2)(3) and (8), on falsehood and exaggeration.
Risk example: “100% effective,” “zero side effects,” or “permanent results from one treatment” without a permissible, substantiated basis.
Consequences: current Article 89 provides a maximum of one year or KRW 10 million for the covered Article 56 violations. The 2024 announcement also cited one-to-two-month institution suspension standards; application depends on the case.
Review direction: use supportable information with its population, period, denominator and limitations. An internal satisfaction percentage is not proof of clinical efficacy or an automatic exemption from advertising review.

4. Missing required review for social, blog or video advertising

Provisions: Article 57 and Enforcement Decree Article 24, covering specified media and exceptions.
Audience threshold: specified internet media and social-network services use a daily average of at least 100,000 users over the three months immediately preceding the previous year-end. This concerns the prescribed medium or provider, rather than an individual clinic account's followers. The current decree carries relevant 2018 amendments; this is not a new blanket rule created in 2024.
Risk example: a clinic publishes treatment advertising on a covered platform without the required review, or uses unapproved material beyond an approved banner. Assess the actual destination and content separately.
Review direction: determine whether the material is medical advertising, whether the medium is covered and whether a content exception applies. Follow the relevant body's instructions for approval numbers and changes; do not assume that every external sentence requires review or that any minor change always invalidates approval.

5. Unsupported “No. 1,” “best” or “only” claims

Provisions: Article 56(2)(3) and (8); qualifications or endorsements can raise additional issues.
Risk example: presenting an unsupported local ranking, exclusive method or superior result as fact.
Review direction: describe verified experience or services precisely, without turning a procedure count into a quality guarantee. Confirm the actual designation or certification and its scope; not every award is an authorized medical endorsement.

6. Misuse of before-and-after photographs

Relevant issues: misleading effects, privacy and the lawful use of patient material, alongside Article 56's content restrictions. A before-and-after image is not automatically the same as exposing a surgical act.
Risk example: reusing a chart photograph without the necessary rights, changing lighting or angles to exaggerate results, or presenting another institution's case as the clinic's own.
Review direction: establish the required consent and permitted use, retain an accurate record of the images and assess the full presentation. Consistent photography and an “individual results vary” statement do not by themselves make an advertisement lawful.

7. Unlawful patient inducement or brokerage

Provision: Article 27(3), including its purpose, scope and statutory exceptions.
Risk conduct: prohibited copayment reductions, money or benefits, transport arrangements or patient introductions undertaken for profit. Assess the actual arrangement rather than classifying every appointment or referral as unlawful.
Consequences: the 2024 ministry announcement summarized a maximum of three years or KRW 30 million and a two-month professional suspension standard. These are legal limits or standards, not an automatic outcome for every contract.
Case assessment: examine the actual judgment and its facts when relying on a past case. The Korean article's brief accounts of website sales and referral payments should not be used to predict a sentence for a different arrangement.
Contract review: scrutinize per-patient or per-treatment payments, platform charges and the services actually performed. A fixed monthly agency fee does not legalize prohibited conduct. Registered foreign-patient attraction has a separate statutory framework that also requires review.

8. Inflated qualifications or experience

Provision: Article 56(2)(9), concerning qualifications and titles without a legal basis.
Risk example: presenting society membership or a short course as a recognized specialist qualification, or using a specialty-hospital designation without the required designation. A genuine academic doctorate, medical licence and specialist qualification are different credentials.
Review direction: state the verified credential, awarding body, specialty and experience accurately. Avoid language that gives a broader impression than the records support.

3. Review the claim, not just the wording

The second column gives a direction for review, not an approved phrase bank. Rewording cannot cure missing evidence, an unlawful incentive or a prohibited testimonial.

Risky claim or use	More appropriate review direction	Relevant starting provision
“Gangnam's No. 1,” “Korea's best,” “the only”	Describe substantiated experience or services, with scope and period; avoid implied superiority.	56(2)(3), (8)
“100% effective,” “zero side effects”	Explain supported benefits and risks. If using data, disclose its basis and limitations.	56(2)(3), (7), (8)
“Permanent results from one treatment”	Describe evidence-based course and recovery expectations without promising a fixed result.	56(2)(8)
“50% off this month” without meaningful terms	Review the comparison price, conditions, period and complete fee information.	56(2)(13)
“Bring a friend and we waive your copayment”	Remove the inducement and assess the actual referral arrangement.	27(3)
“Write a review for a treatment refund”	Do not offer that incentive; assess the medical-advertising and inducement issues.	27(3), 56
“Guaranteed treatment” or “guaranteed cure”	Explain the options and suitability factors that require individual assessment.	56(2)(2), (3), (8)
“Popular with famous celebrities”	Omit unsupported associations and protect patient information.	56 and applicable privacy rules
“Patient X is delighted with the result”	Assess testimonial restrictions; consent or anonymity alone does not authorize it.	56(2)(2)
An unsupported “doctor of [procedure]” title	Use the actual licence, academic degree or professional membership accurately.	56(2)(9)
“Specialty hospital” without designation	Use the institution's lawful name and actual designation.	56(2)(9)
“Absolutely no adverse effects”	Explain the actual assessment and material risks; screening does not eliminate every risk.	56(2)(7), (8)
Before-and-after photographs without proper rights	Resolve lawful use, consent and accurate presentation, then review the advertisement as a whole.	56 and applicable privacy rules
“Google five stars” or “No. 1 Naver rating”	Check the source, date, sample, meaning and permissibility of the claim.	56(2)(3), (8)

Use the table with your agency for an initial review. Keep the evidence and the actual proposed advertisement beside it.

4. Applying for review: process, fees and validity

The relevant review body

Medical practitioners and relevant medical institutions: the Korean Medical Association's medical-advertising review committee.
Dental practitioners and institutions: the Korean Dental Association's review service.
Korean medicine practitioners and institutions: the Association of Korean Medicine's review service.

A typical application sequence

Confirm the competent body and create the required applicant account.
Submit the complete proposed advertisement, including the relevant text, images, video and destination information.
Pay the applicable review fee.
Allow time for review and any requested corrections; the original article's two-to-four-week estimate is not a guaranteed current service period.
Check the decision and all conditions before preparing the final version.
Use the approval number and approved material in accordance with the body's instructions.

Review fees

Fees depend on the body, medium and application type. Confirm the current schedule before submitting. This guide does not quote a fee or claim that the same price or timetable applies to every body.

Validity and changes

Article 57 establishes three-year validity and an application six months before expiry for continued use. Keep the approved version, scope and expiry date. For edits or excerpts, check whether notification, amendment or another review is required; do not assume either unrestricted reuse or automatic cancellation for every change.

5. Preparing useful AEO content within the advertising rules

A clinic can give patients useful, specific information while checking the advertiser, content and medium. Four principles help organize that work.

Principle 1: support claims with appropriate evidence

Document what a statistic measures, who was included, the period, denominator and limitations. Clinical effects need suitable clinical evidence. Internal figures, a first-person account or a research citation do not automatically turn medical advertising into non-advertising information.

Principle 2: answer genuine questions clearly

A short answer followed by the necessary explanation can help a patient understand the topic. Keep material risks and conditions attached to the answer. FAQ formatting does not itself create a legal exception or guarantee an AI citation; Google no longer displays FAQ rich results.

Principle 3: make claim review part of the publishing process

Use the eight categories and wording table to flag issues before publication. Check the full statement and evidence rather than merely replacing banned words. Record what remains for clinical or legal review.

Principle 4: assess review requirements for each proposed publication

Check whether the material is a medical advertisement, whether its medium is covered by Article 57 and Decree Article 24, and whether the limited-information exception applies. Material outside advance review still must comply with the law. Use a valid approval where required and keep the published version within its approved scope.

6. Make compliance part of everyday clinic marketing

The targeted 2024 monitoring exercise is a reason to review advertising carefully, not proof that most clinics are currently in violation. It shows how one advertisement can raise several distinct issues.

We recommend agreeing with the clinic and agency on who checks clinical accuracy, claims and evidence, privacy, media requirements and the final approved version. That is more reliable than treating a reassuring phrase or a satisfaction percentage as automatic permission to publish.

Contact BlinkAd about a review of your clinic's public content. We can help organize the content questions and identify material that needs the relevant specialist or review body's assessment. Reviewing marketing copy does not replace legal advice, clinical approval or formal advertising approval.

Sources and reading notes

Ministry of Health and Welfare, March 11, 2024 monitoring announcement, read in the Chungcheongbuk-do government republication.
Medical Service Act Article 56, current provision checked October 31, 2026.
Article 57, including review exceptions and paragraphs 8–9 on validity.
Article 27(3), the patient-inducement provision cited by the ministry; its statutory scope and exceptions matter.
Professional and institutional administrative measures are distinct; use the applicable current disposition rules for an individual case.
Article 89, current criminal maximum for the specified advertising violations.
Enforcement Decree Article 24, covered media, audience threshold and limited-information categories.
The source announcement distinguishes 409 monitored items, 366 referrals and 506 potentially unlawful content items.
The source's printed 183/31.7% figure conflicts arithmetically with its stated 506-item denominator; this edition does not silently adopt it.
The ministry's medical-advertising guidance is supplementary to the current statute and applicable review instructions.
The Korean original's press summaries were background; the primary announcement and provisions are the basis of this edition's legal summary.
The media threshold is not a clinic-account follower threshold, and not every public item is automatically subject to advance review.
The Korean Medical Association route should be confirmed directly for the relevant institution and application.
Korean Dental Association review FAQ, including media scope, exceptions and renewal guidance.
Association of Korean Medicine review service; some older explanatory text should be read alongside current legislation.
Professional guidance or an agency's wording table is not a substitute for the relevant body's decision.
A paid testimonial's sponsorship disclosure does not resolve every medical-advertising issue.
Consent, privacy and advertising permissibility require separate assessment.
KHIDI's foreign-patient attraction legal information, for the separate registration and inducement framework.
Google's 2026 updates, recording the end of FAQ rich results; content usefulness and legal review remain separate.

BlinkAd is a Google and AI marketing agency helping businesses prepare for international customers' searches, visits and inquiries.